The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback